|Description||AS605240 is a selective PI3Kgamma inhibitor, has been proved effective on several inflammatory diseases. Orally administration of AS605240 significantly prevented lung inflammation and reduced collagen deposition. AS605240 also inhibited augmented expression of TNF-alpha and IL-1beta induced by bleomycin instillation. AS605240 may be a useful in treating inflammation diseases. AS605240 may represent a promising novel agent for the future therapy of pulmonary fibrosis.|
|Synonyms||AS 605240; AS605240; AS-605240.|
Idelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
TGR-1202 hydrochloride is the hydrochloride salt of TGR-1202.TGR-1202, also known as RP5264, is a highly specific, orally available, PI3Kdelta inhibitor which i...
In the absence of PTEN phosphatase tumor suppressor function, PI3Kγ or PI3Kδ alone can support leukemogenesis, whereas inactivation of both isoforms suppressed ...
PIK-93 is a potent PI3K inhibitor.
ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after o...
GDC-0077 is an orally available and selective PI3K inhibitor (IC50 = 0.038 + 0.003 nM) with > 300-fold selective over other Class I PI3K isoforms. GDC-0077 exer...
PI3Kα inhibitor 1
PI3Kα inhibitor 1 is an inhibitor of PI3Kα as well as HDAC and probably have antineoplastic activity. IC50: ＜0.1 μM.
VPS34-IN1 is a potent and selective Vps34 inhibitor with potential anticancer activity. VPS34-IN1 inhibits Vps34 with 25 nM IC50 in vitro.